Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study developed a silk fibroin/poly(vinyl alcohol) microneedle loaded with α-aminoxyacetate and HfO₂ nanoparticles for vitiligo treatment, which protected against ROS damage and modulated immune responses, leading to improved melanogenesis and skin repigmentation.

5-ARI therapy may help prevent prostate cancer progression.

This study reported that compounds from the root of Beta vulgaris, specifically 4-picoline and Betalain, showed potential as effective anti-hair loss treatments by demonstrating significant inhibitory activity against the enzyme 5α-reductase in a computational molecular docking study.

This paper discusses a structure-based analysis to find new BRD4 inhibitors, identifying finasteride and amentoflavone as promising candidates for BET inhibition.

In this study, simvastatin/ezetimibe treatment led to partial hair regrowth in about 29% of patients with recalcitrant alopecia areata, suggesting it may be a viable alternative therapy for this condition.

This review discusses the potential of using triads of repositioned medicines targeting multiple pathogenic mechanisms to prevent or delay retina degeneration, but reports no new results.

This case report describes a Japanese bone marrow transplant recipient who developed a high-risk cutaneous squamous cell carcinoma on the scalp, potentially linked to long-term voriconazole use.

This study found that ritlecitinib was well tolerated in children aged 6 to under 12 years with severe alopecia areata, with ongoing trials examining its efficacy and safety over a 24-week period and in long-term use up to 36 months.

This source reports on advances in stimulus-responsive nanoparticle-based PROTACs (nano-PROTACs), which aim to overcome existing challenges like poor cell permeability and systemic off-target effects by enabling controlled protein degradation through endogenous or exogenous stimuli, potentially enhancing therapeutic efficacy and reducing toxicity.

This study suggests that monitoring CD8+ TEMRA cells in patients with rapidly progressive alopecia areata treated with intravenous corticosteroids could help predict therapeutic outcomes.

This study found that for metastatic colorectal cancer patients, substituting calcium folinate with disodium folinate in combination with fluorouracil and oxaliplatin showed similar effectiveness and safety as the mFOLFOX6 regimen.

This study reviewed evidence suggesting that systemic corticosteroids, particularly in pulse regimens like dexamethasone and betamethasone oral mini-pulse, effectively slow vitiligo progression and support repigmentation, while offering a favorable safety profile compared to continuous therapy.

In this study, tofacitinib showed promising efficacy and safety for biologic-naïve elderly patients with moderate-to-severe ulcerative colitis, achieving steroid-free remission and clinical response over 52 weeks.

This study reports the discovery of LX-38, a novel non-steroidal drug candidate that may offer safer treatment for conditions like Benign Prostatic Hyperplasia by avoiding hormonal side effects associated with current therapies.

This study found that in vivo, a novel microneedle system for valproic acid delivery may improve hair regrowth efficacy by upregulating hair follicle development pathways more effectively than topical application.

This review discusses Hedgehog inhibitors for basal cell carcinoma treatment, noting tumor regression during therapy but also challenges like muscle toxicity and potential resistance; it reports no new clinical findings.

In a rodent study, researchers found that oral phenytoin and spironolactone significantly mitigated 5-fluorouracil-induced hair loss and oxidative stress, suggesting potential therapeutic benefits for chemotherapy-induced alopecia and enhanced recovery.

This study evaluated the effectiveness and safety of ritlecitinib in patients aged 12 or older with alopecia totalis or universalis, finding higher hair regrowth response rates compared to placebo at 24 weeks, with continued improvement and acceptable safety through 48 weeks.

This study found that an extract from the herbal medicine Ophioglossum vulgatum Linn. showed potential hair growth promotion and increased ATP and catalase activity in cell assays, suggesting its use in treating alopecia.

This study investigated a new formula called SV-loaded nanospanlastics for topical application to treat androgenic alopecia. It showed similar effectiveness to minoxidil lotion but with fewer adverse effects when used to enhance dermal delivery and efficacy of sodium valproate.

This study developed a 3D ovarian cancer model using microtumours, which effectively mimics minimal residual disease and supports the identification of new drug targets like perhexiline for treatment-resistant cells.

This study reports the first successful use of zanubrutinib to treat a 15-year-old Chinese girl with severe refractory Evans' syndrome, resulting in a sustained recovery of platelet counts and haemoglobin levels.

Tofacitinib helped regrow hair in a patient with severe hair loss and improved their quality of life without side effects.

This review highlights recent progress in developing androgen receptor degraders, such as PROTACs, for treating castration-resistant prostate cancer, and notes that several have entered phase I or II clinical trials, showcasing potential to address drug resistance challenges.

This study found that finasteride- and dutasteride-loaded iron oxide nanoparticles improved drug penetration in the skin, suggesting they may be promising for topical alopecia therapies.

In this first-in-human study, BLZ-100, an intraoperative fluorescent imaging agent, was administered to 21 patients before skin cancer surgery and was found to be well tolerated without serious adverse effects, suggesting its potential to help distinguish cancerous from non-cancerous tissue based on fluorescence.

This case report highlights the rare occurrence of life-threatening aplastic anemia in a 65-year-old woman treated with temozolomide for glioblastoma multiforme, emphasizing the need for more frequent blood monitoring to detect severe bone marrow suppression early.

This report describes a case of alopecia totalis associated with lopinavir/ritonavir in an HIV-positive patient, which reversed after discontinuation of the drug.

In this institution-based randomized trial, oral betamethasone mini-pulse therapy for alopecia areata showed a faster therapeutic response compared to oral tofacitinib, as measured by trichoscopic changes and achievement of 50% hair regrowth.